Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 12, 2015, Pages 2152-2165

  Ilyas, Sumera I ^a   Eaton, John E ^a   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Biliary Dysplasia; Chemoprevention; Interleukin 6; Perihilar Cholangiocarcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; DNA; FLUORODEOXYGLUCOSE F 18;

ADJUVANT CHEMORADIOTHERAPY; BILE DUCT CARCINOMA; BILIARY TRACT SURGERY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CHOLESTASIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CYTODIAGNOSIS; DISEASE SURVEILLANCE; DNA DAMAGE; DNA METHYLATION; DYSPLASIA; EARLY DIAGNOSIS; ECHOGRAPHY; EXTRACELLULAR MATRIX; FLUORESCENCE IN SITU HYBRIDIZATION; HIGH RISK PATIENT; HUMAN; INFLAMMATION; LIVER TRANSPLANTATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; RISK FACTOR; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; BILIARY TRACT NEOPLASMS; CHEMOPROPHYLAXIS; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; COMPLICATION; DIAGNOSTIC TEST; EPIDEMIOLOGICAL MONITORING; PROCEDURES;

BILIARY TRACT NEOPLASMS; CHEMOPREVENTION; CHEMORADIOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; DIAGNOSTIC TESTS, ROUTINE; EPIDEMIOLOGICAL MONITORING; HUMANS; LIVER TRANSPLANTATION;

EID: 84944410966     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.05.035     Document Type: Review

References (100)

1. Rizvi S., Borad M.J., Patel T., et al. Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin Liver Dis 2014, 34:456-464.
2. Boonstra K., Weersma R.K., van Erpecum K.J., et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013, 58:2045-2055.
3. Kornfeld D., Ekbom A., Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: a population-based study. Scand J Gastroenterol 1997, 32:1042-1045.
4. de Valle M.B., Bjornsson E., Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int 2012, 32:441-448.
5. Rizvi S., Gores G.J. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion 2014, 89:216-224.
6. Lewis J.T., Talwalkar J.A., Rosen C.B., et al. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol 2010, 34:27-34.
7. Kerr S.E., Barr Fritcher E.G., Campion M.B., et al. Biliary dysplasia in primary sclerosing cholangitis harbors cytogenetic abnormalities similar to cholangiocarcinoma. Hum Pathol 2014, 45:1797-1804.
8. Fleming K.A., Boberg K.M., Glaumann H., et al. Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2001, 34:360-365.
9. Razumilava N., Gores G.J., Lindor K.D. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011, 54:1842-1852.
10. Bergquist A., Ekbom A., Olsson R., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36:321-327.
11. Boberg K.M., Bergquist A., Mitchell S., et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002, 37:1205-1211.
12. Burak K., Angulo P., Pasha T.M., et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004, 99:523-526.
13. Chalasani N., Baluyut A., Ismail A., et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000, 31:7-11.
14. Bergquist A., Glaumann H., Persson B., et al. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998, 27:311-316.
15. Broome U., Lofberg R., Veress B., et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995, 22:1404-1408.
16. Singal A.K., Stanca C.M., Clark V., et al. Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature. Hepatol Int 2011, 5:808-813.
17. Bjornsson E., Angulo P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am J Gastroenterol 2007, 102:1677-1682.
18. Deneau M., Jensen M.K., Holmen J., et al. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology 2013, 58:1392-1400.
19. Rupp C., Rossler A., Halibasic E., et al. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther 2014, 40:1292-1301.
20. Al Mamari S., Djordjevic J., Halliday J.S., et al. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013, 58:329-334.
21. Saarinen S., Olerup O., Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:3195-3199.
22. Eaton J.E., Talwalkar J.A., Lazaridis K.N., et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013, 145:521-536.
23. Olerup O., Olsson R., Hultcrantz R., et al. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1995, 108:870-878.
24. Spurkland A., Saarinen S., Boberg K.M., et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999, 53:459-469.
25. Liu J.Z., Hov J.R., Folseraas T., et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013, 45:670-675.
26. Karlsen T.H., Franke A., Melum E., et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010, 138:1102-1111.
27. Melum E., Franke A., Schramm C., et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011, 43:17-19.
28. Rizvi S., Gores G.J. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013, 145:1215-1229.
29. Jaiswal M., LaRusso N.F., Burgart L.J., et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000, 60:184-190.
30. Jaiswal M., LaRusso N.F., Shapiro R.A., et al. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 2001, 120:190-199.
31. Ichim G., Lopez J., Ahmed S.U., et al. Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol Cell 2015, 57:860-872.
32. Liu X., He Y., Li F., et al. Caspase-3 promotes genetic instability and carcinogenesis. Mol Cell 2015, 58:284-296.
33. Lovric M.M., Hawkins C.J. TRAIL treatment provokes mutations in surviving cells. Oncogene 2010, 29:5048-5060.
34. Takeda K., Kojima Y., Ikejima K., et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci U S A 2008, 105:10895-10900.
35. Yoon J.-H., Higuchi H., Werneburg N.W., et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002, 122:985-993.
36. Yoon J.H., Gwak G.Y., Lee H.S., et al. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 2004, 41:808-814.
37. Kuver R. Mechanisms of oxysterol-induced disease: insights from the biliary system. Clin Lipidol 2012, 7:537-548.
38. Haigh W.G., Lee S.P. Identification of oxysterols in human bile and pigment gallstones. Gastroenterology 2001, 121:118-123.
39. Yoon J.H., Canbay A.E., Werneburg N.W., et al. Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. Hepatology 2004, 39:732-738.
40. Dwyer J.R., Sever N., Carlson M., et al. Oxysterols are novel activators of the hedgehog signaling pathway in pluripotent mesenchymal cells. J Biol Chem 2007, 282:8959-8968.
41. El Khatib M., Kalnytska A., Palagani V., et al. Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. Hepatology 2013, 57:1035-1045.
42. Fingas C.D., Bronk S.F., Werneburg N.W., et al. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology 2011, 54:2076-2088.
43. Nachtergaele S., Mydock L.K., Krishnan K., et al. Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat Chem Biol 2012, 8:211-220.
44. Yamada D., Rizvi S., Razumilava N., et al. IL-33 facilitates oncogene driven cholangiocarcinoma in mice. Hepatology 2014, 60:641a-642a.
45. Li J., Razumilava N., Gores G.J., et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest 2014, 124:3241-3251.
46. Marvie P., Lisbonne M., L'Helgoualc'h A., et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med 2010, 14:1726-1739.
47. Park J., Tadlock L., Gores G.J., et al. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999, 30:1128-1133.
48. Taniguchi K., Wu L.W., Grivennikov S.I., et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 2015, 519:57-62.
49. Sandborn W.J., Ghosh S., Panes J., et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012, 367:616-624.
50. Jhaveri K.S., Hosseini-Nik H. MRI of cholangiocarcinoma. J Magn Reson Imaging 2014, [Epub ahead of print].
51. Charatcharoenwitthaya P., Enders F.B., Halling K.C., et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008, 48:1106-1117.
52. Chapman R., Fevery J., Kalloo A., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010, 51:660-678.
53. Stiehl A., Rudolph G., Kloters-Plachky P., et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002, 36:151-156.
54. Sangfelt P., Sundin A., Wanders A., et al. Monitoring dominant strictures in primary sclerosing cholangitis with brush cytology and FDG-PET. J Hepatol 2014, 61:1352-1357.
55. Kaya M., Petersen B.T., Angulo P., et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1059-1066.
56. Eaton J.E., Barr Fritcher E.G., Gores G.J., et al. Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2015, 110:299-309.
57. Outwater E., Kaplan M.M., Bankoff M.S. Lymphadenopathy in sclerosing cholangitis: pitfall in the diagnosis of malignant biliary obstruction. Gastrointest Radiol 1992, 17:157-160.
58. Wannhoff A., Hov J.R., Folseraas T., et al. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 2013, 59:1278-1284.
59. Levy C., Lymp J., Angulo P., et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005, 50:1734-1740.
60. Sinakos E., Saenger A.K., Keach J., et al. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol 2011, 9:434-439.
61. Venkatesh P.G., Navaneethan U., Shen B., et al. Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci 2013, 58:850-857.
62. Eaton J.E., Gossard A.A., Talwalkar J.A. Recall processes for biliary cytology in primary sclerosing cholangitis. Curr Opin Gastroenterol 2014, 30:287-294.
63. Trikudanathan G., Navaneethan U., Njei B., et al. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014, 79:783-789.
64. Furmanczyk P.S., Grieco V.S., Agoff S.N. Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels. Am J Clin Pathol 2005, 124:355-360.
65. Barr Fritcher E.G., Voss J.S., Jenkins S.M., et al. Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy. Cancer Cytopathol 2013, 121:708-717.
66. Bangarulingam S.Y., Bjornsson E., Enders F., et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 2010, 51:174-180.
67. Barr Fritcher E.G., Kipp B.R., Voss J.S., et al. Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am J Gastroenterol 2011, 106:2023-2028.
68. Navaneethan U., Njei B., Venkatesh P.G., et al. Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014, 79:943-950.
69. Siddiqui A.A., Mehendiratta V., Jackson W., et al. Identification of cholangiocarcinoma by using the Spyglass Spyscope system for peroral cholangioscopy and biopsy collection. Clin Gastroenterol Hepatol 2012, 10:466-471. quiz e48.
70. Domagk D., Wessling J., Reimer P., et al. Endoscopic retrograde cholangiopancreatography, intraductal ultrasonography, and magnetic resonance cholangiopancreatography in bile duct strictures: a prospective comparison of imaging diagnostics with histopathological correlation. Am J Gastroenterol 2004, 99:1684-1689.
71. Meining A., Frimberger E., Becker V., et al. Detection of cholangiocarcinoma in vivo using miniprobe-based confocal fluorescence microscopy. Clin Gastroenterol Hepatol 2008, 6:1057-1060.
72. Azeem N., Gostout C.J., Knipschield M., et al. Cholangioscopy with narrow-band imaging in patients with primary sclerosing cholangitis undergoing ERCP. Gastrointest Endosc 2014, 79:773-779.
73. Boberg K.M., Jebsen P., Clausen O.P., et al. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006, 45:568-574.
74. Andresen K., Boberg K.M., Vedeld H.M., et al. Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma. Hepatology 2015, 61:1651-1659.
75. Heimbach J.K., Sanchez W., Rosen C.B., et al. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB 2011, 13:356-360.
76. Laird P.W. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003, 3:253-266.
77. Shin S.H., Lee K., Kim B.H., et al. Bile-based detection of extrahepatic cholangiocarcinoma with quantitative DNA methylation markers and its high sensitivity. J Mol Diagn 2012, 14:256-263.
78. Shigehara K., Yokomuro S., Ishibashi O., et al. Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One 2011, 6:e23584.
79. Baraniskin A., Nopel-Dunnebacke S., Ahrens M., et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J Cancer 2013, 132:E48-E57.
80. Baraniskin A., Nopel-Dunnebacke S., Schumacher B., et al. Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Dig Dis Sci 2014, 59:1436-1441.
81. Li L., Masica D., Ishida M., et al. Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology 2014, 60:896-907.
82. Arasaradnam R.P., Covington J.A., Harmston C., et al. Review article: next generation diagnostic modalities in gastroenterology-gas phase volatile compound biomarker detection. Aliment Pharmacol Ther 2014, 39:780-789.
83. Navaneethan U., Parsi M.A., Lourdusamy V., et al. Volatile organic compounds in bile for early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis: a pilot study. Gastrointest Endosc 2015, 81:943-949.
84. Navaneethan U., Gutierrez N.G., Venkatesh P.G., et al. Lipidomic profiling of bile in distinguishing benign from malignant biliary strictures: a single-blinded pilot study. Am J Gastroenterol 2014, 109:895-902.
85. Lankisch T.O., Metzger J., Negm A.A., et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 2011, 53:875-884.
86. Metzger J., Negm A.A., Plentz R.R., et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 2013, 62:122-130.
87. Voigtlander T., David S., Thamm K., et al. Angiopoietin-2 and biliary diseases: elevated serum, but not bile levels are associated with cholangiocarcinoma. PLoS One 2014, 9:e97046.
88. Chapman M.H., Sandanayake N.S., Andreola F., et al. Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer. J Clin Exp Hepatol 2011, 1:6-12.
89. Lempinen M., Isoniemi H., Makisalo H., et al. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol 2007, 47:677-683.
90. Sandanayake N.S., Sinclair J., Andreola F., et al. A combination of serum leucine-rich alpha-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer 2011, 105:1370-1378.
91. Rosen C.B., Nagorney D.M. Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin Liver Dis 1991, 11:26-30.
92. Rosen C.B., Nagorney D.M., Wiesner R.H., et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991, 213:21-25.
93. Rea D.J., Rosen C.B., Nagorney D.M., et al. Transplantation for cholangiocarcinoma: when and for whom?. Surg Oncol Clin N Am 2009, 18:325-337. ix.
94. Ghali P., Marotta P.J., Yoshida E.M., et al. Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl 2005, 11:1412-1416.
95. Darwish Murad S., Kim W.R., Harnois D.M., et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012, 143:88-98. quiz e14.
96. Darwish Murad S., Kim W.R., Therneau T., et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology 2012, 56:972-981.
97. Nikeghbalian S., Shamsaeefar A., Eshraghian A., et al. Liver transplantation and Whipple surgery combined with chemo-radiotherapy for treatment of hilar cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver Transpl 2015, 21:696-699.
98. Wu Y., Johlin F.C., Rayhill S.C., et al. Long-term, tumor-free survival after radiotherapy combining hepatectomy-Whipple en bloc and orthotopic liver transplantation for early-stage hilar cholangiocarcinoma. Liver Transpl 2008, 14:279-286.
99. Valle J., Wasan H., Palmer D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362:1273-1281.
100. Borad M.J., Champion M.D., Egan J.B., et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. Plos Genet 2014, 10:e1004135.